Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Apollo Endosurgery Company

APEN
US03767D1081
A2DJ26

Price

10.00
Today +/-
+0
Today %
+0 %
P

Apollo Endosurgery stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Apollo Endosurgery stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Apollo Endosurgery stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Apollo Endosurgery stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Apollo Endosurgery's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Apollo Endosurgery Stock Price History

DateApollo Endosurgery Price
4/11/202310.00 undefined
4/10/202310.00 undefined

Apollo Endosurgery Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Apollo Endosurgery, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Apollo Endosurgery from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Apollo Endosurgery’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Apollo Endosurgery. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Apollo Endosurgery’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Apollo Endosurgery’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Apollo Endosurgery’s growth potential.

Apollo Endosurgery Revenue, EBIT and net profit per share

DateApollo Endosurgery RevenueApollo Endosurgery EBITApollo Endosurgery Net Income
2026e131.47 M undefined-27.64 M undefined-42.34 M undefined
2025e184.47 M undefined-27.67 M undefined-37.27 M undefined
2024e111.2 M undefined-26.05 M undefined-34.92 M undefined
2023e91.02 M undefined-29.62 M undefined-40.45 M undefined
202276.86 M undefined-27.82 M undefined-39.84 M undefined
202162.99 M undefined-19.2 M undefined-24.68 M undefined
202042.05 M undefined-15.79 M undefined-22.61 M undefined
201950.71 M undefined-29.12 M undefined-27.43 M undefined
201860.85 M undefined-32.32 M undefined-45.79 M undefined
201764.31 M undefined-22.44 M undefined-27.29 M undefined
201664.65 M undefined-20.76 M undefined-41.17 M undefined
201567.79 M undefined-16.68 M undefined-36.38 M undefined
20145.08 M undefined-17.81 M undefined-16.56 M undefined
20137.99 M undefined-7.59 M undefined-6.56 M undefined
20126.69 M undefined-5.56 M undefined-2.75 M undefined
20119.39 M undefined-3.71 M undefined-3.11 M undefined
20107.84 M undefined-4.49 M undefined-4.6 M undefined
200911.91 M undefined1.8 M undefined3.98 M undefined
20082.86 M undefined-11.74 M undefined-11.46 M undefined
2007370,000 undefined-15.48 M undefined-15.09 M undefined

Apollo Endosurgery Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (k)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
021179675676464605042627691111184131
--450.00-36.3628.57-33.3316.67-28.571,240.00-4.48--6.25-16.67-16.0047.6222.5819.7421.9865.77-28.80
--------70.1560.9460.9455.0050.0052.3854.8455.26----
0000000047393933252234420000
-15,000-11,0001,000-4,000-3,000-5,000-7,000-17,000-16,000-20,000-22,000-32,000-29,000-15,000-19,000-27,000-29,000-26,000-27,000-27,000
--550.009.09-57.14-33.33-83.33-100.00-340.00-23.88-31.25-34.38-53.33-58.00-35.71-30.65-35.53-31.87-23.42-14.67-20.61
-15-113-4-3-2-6-16-36-41-27-45-27-22-24-39-40-34-37-42
--26.67-127.27-233.33-25.00-33.33200.00166.67125.0013.89-34.1566.67-40.00-18.529.0962.502.56-15.008.8213.51
0.070.090.110.10.120.140.170.210.240.3913.5719.7921.5422.7630.2440.650000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The Apollo Endosurgery Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Apollo Endosurgery is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2007200820092010201120122013201420152016201720182019202020212022
                               
7.57.86.26.814.424.611.917.321.719.130.52429.936.290.6957
00.70.315.41.30.21.30.710.510.511.711.49.28.210.0814.99
0000000000000000
0000000012.812.214.39.98.910.311.9718.25
0.20.20.20.20.30.30.30.42.11.812.833.81.972.64
7.78.76.722.41625.113.518.447.143.657.548.15158.5114.792.88
0.40.30.20.10.20.30.20.286.96.95.96.66.25.597.51
0000000000000000
0000000000000000
0.40.50.91.31.61.71.92.24943.336.49.97.864.43.12
000000000.26.86.85.35.35.35.295.29
00000.10.10.10.111.51.35.33.81.41.551.44
0.80.81.11.41.92.12.22.558.258.551.426.423.518.916.8317.35
8.59.57.823.817.927.215.720.9105.3102.1108.974.574.577.4131.53110.23
                               
00.10.10.10000144.9000000.040.04
34.543.134.34040.857.859.481.8-25.2190.7225.1249.1250.6276.6356.52364.87
-28.2-39.6-32.4-37-40.2-42.9-49.5-66-108.6-149.7-177-222.8-250.2-272.8-297.46-337.29
0000000001.51.82.51.62.92.144.97
0000000000000000
6.33.623.10.614.99.915.811.142.549.928.826.761.2432.59
11.10.30.52.2122.94.75.118.315.39.93.74.587.42
0.60.90.92.31.82.211.26.46.47.59.26.87.49.912.4
03.40.76.76.15.40.50.210.28.7001.6000
0000000000000000
00000000000034.40.6019.71
1.65.41.99.510.18.63.54.321.320.225.824.552.711.714.4939.54
0000000069.839.433.321.218.656.652.9933.96
0000000000000000
0.70.54.111.47.23.62.20.92.90001.12.42.824.14
0.70.54.111.47.23.62.20.972.739.433.321.219.75955.8138.1
2.35.9620.917.312.25.75.29459.659.145.772.470.770.2977.64
8.69.582417.927.115.621105.1102.110974.574.477.4131.53110.23
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Apollo Endosurgery provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Apollo Endosurgery's financial health and stability.

Assets

Apollo Endosurgery's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Apollo Endosurgery must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Apollo Endosurgery after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Apollo Endosurgery's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2007200820092010201120122013201420152016201720182019202020212022
-15-113-4-3-2-6-16-27-41-27-45-27-22-24-39
0000000089994332
0000000000000000
13-3010-3-61-30110-70-6
21-110-200618211-25612
0000000045333362
0000000000000000
-10-6-1-38-8-13-15-16-12-13-23-25-20-14-31
00000000-6-2-2-200-1-2
00000000-6-2-27111-2
00000000000102230
0000000000000000
0000000034-11-7-12332-30
176040190210293322023720
1760401802133122693025670
---------1.00-5.00---2.00--1.00-
0000000000000000
60-10710-12510-211-65654-33
-11.2-6.31-1.62-4.067.57-8.65-13.54-15.73-22.79-15.27-15.46-26-26.6-21.44-15.91-34.01
0000000000000000

Apollo Endosurgery stock margins

The Apollo Endosurgery margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Apollo Endosurgery. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Apollo Endosurgery.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Apollo Endosurgery's sales revenue. A higher gross margin percentage indicates that the Apollo Endosurgery retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Apollo Endosurgery's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Apollo Endosurgery's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Apollo Endosurgery's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Apollo Endosurgery. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Apollo Endosurgery's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Apollo Endosurgery Margin History

Apollo Endosurgery Gross marginApollo Endosurgery Profit marginApollo Endosurgery EBIT marginApollo Endosurgery Profit margin
2026e55.2 %-21.02 %-32.21 %
2025e55.2 %-15 %-20.2 %
2024e55.2 %-23.43 %-31.4 %
2023e55.2 %-32.54 %-44.44 %
202255.2 %-36.2 %-51.84 %
202155.5 %-30.48 %-39.18 %
202052.89 %-37.55 %-53.77 %
201950.64 %-57.42 %-54.09 %
201854.54 %-53.11 %-75.25 %
201761.78 %-34.89 %-42.44 %
201660.94 %-32.11 %-63.68 %
201569.74 %-24.61 %-53.67 %
201455.2 %-350.59 %-325.98 %
201355.2 %-94.99 %-82.1 %
201255.2 %-83.11 %-41.11 %
201155.2 %-39.51 %-33.12 %
201055.2 %-57.27 %-58.67 %
200955.2 %15.11 %33.42 %
200855.2 %-410.49 %-400.7 %
200755.2 %-4,183.78 %-4,078.38 %

Apollo Endosurgery Stock Sales Revenue, EBIT, Earnings per Share

The Apollo Endosurgery earnings per share therefore indicates how much revenue Apollo Endosurgery has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Apollo Endosurgery earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Apollo Endosurgery's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Apollo Endosurgery’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Apollo Endosurgery's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Apollo Endosurgery Revenue, EBIT and net profit per share

DateApollo Endosurgery Sales per ShareApollo Endosurgery EBIT per shareApollo Endosurgery Earnings per Share
2026e2.76 undefined0 undefined-0.89 undefined
2025e3.88 undefined0 undefined-0.78 undefined
2024e2.34 undefined0 undefined-0.73 undefined
2023e1.91 undefined0 undefined-0.85 undefined
20221.89 undefined-0.68 undefined-0.98 undefined
20212.08 undefined-0.63 undefined-0.82 undefined
20201.85 undefined-0.69 undefined-0.99 undefined
20192.35 undefined-1.35 undefined-1.27 undefined
20183.07 undefined-1.63 undefined-2.31 undefined
20174.74 undefined-1.65 undefined-2.01 undefined
2016165.77 undefined-53.23 undefined-105.56 undefined
2015282.46 undefined-69.5 undefined-151.58 undefined
201424.19 undefined-84.81 undefined-78.86 undefined
201347 undefined-44.65 undefined-38.59 undefined
201247.79 undefined-39.71 undefined-19.64 undefined
201178.25 undefined-30.92 undefined-25.92 undefined
201078.4 undefined-44.9 undefined-46 undefined
2009108.27 undefined16.36 undefined36.18 undefined
200831.78 undefined-130.44 undefined-127.33 undefined
20075.29 undefined-221.14 undefined-215.57 undefined

Apollo Endosurgery business model

Apollo Endosurgery Inc is a medical technology company based in Austin, Texas that specializes in minimally invasive surgical technologies and products. It was founded in 2005 and has since become one of the leading providers of endoscopic instruments and systems. The business model of Apollo Endosurgery is based on the development and marketing of innovative products for minimally invasive surgery. The company focuses on three main areas: bariatric surgery, gastrointestinal surgery, and endoscopic surgery. The goal is to provide patients with minimally invasive solutions that are less invasive, safer, and more effective than traditional surgical methods. In the field of bariatric surgery, Apollo Endosurgery offers a wide range of products for the treatment of obese patients. This includes the bioabsorbable Orbera gastric balloon system, which provides a non-surgical alternative for weight reduction. It is introduced endoscopically into the stomach and can reduce the volume of the stomach, resulting in a faster feeling of satiety. The system needs to be removed after six months, but studies have shown that it can lead to significant weight loss. In the gastrointestinal surgery sector, Apollo Endosurgery offers the OverStitch system for endoscopic sutures. This system allows for the safe and easy performance of sutures in hard-to-reach areas of the GI tract without the need for open surgery. The system can be used for a variety of applications, including the treatment of fistulas and sealing leaks in the esophagus and intestine. Apollo Endosurgery's endoscopic surgery division focuses on the development of instruments and systems for endoscopic procedures. This includes the OverStitch system, as well as the Flex-Endoflex system for endoscopic procedures in the biliary system. These products enable safer and more effective procedures. Overall, Apollo Endosurgery has developed a wide range of products for minimally invasive surgery, offering doctors and patients a variety of treatment options. The company has also evolved through acquisitions, such as the acquisition of the biopolymer-based Orbera system by Apollo Endosurgery Inc. The company has a strong international presence, operating in Europe, Asia, and the USA, and has numerous partners in these regions. It has established close relationships with key clinics and physicians and is actively involved in researching and developing new technologies for minimally invasive surgery. In conclusion, Apollo Endosurgery Inc is a leading medical technology company focused on the development of innovative products for minimally invasive surgery. The company offers a wide range of products for bariatric, gastrointestinal, and endoscopic surgery and has strong relationships with key clinics and physicians. Apollo Endosurgery has a strong international presence and consistently works on researching and developing new technologies to provide minimally invasive solutions for patients worldwide. Apollo Endosurgery is one of the most popular companies on Eulerpool.com.

Apollo Endosurgery Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Apollo Endosurgery Revenue by Segment

Segmente2022202120202019201820172016
ESS53.85 M USD39.97 M USD25.73 M USD28.31 M USD---
IGB22.26 M USD22.1 M USD14.78 M USD16.84 M USD---
Endo-Bariatric---45.15 M USD---
Total Endoscopy--40.51 M USD----
Other748,000 USD927,000 USD1.54 M USD1.85 M USD---
Surgical---3.71 M USD---
Endo-Bariatric----41.12 M USD35.92 M USD-
Surgical----18.71 M USD27.59 M USD-
ESS----23.38 M USD--
IGB----17.74 M USD--
Other----1.03 M USD794,000 USD-
Endo-Bariatric------16.38 M USD
Surgical------10.71 M USD
Other------24,000 USD

Apollo Endosurgery Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Apollo Endosurgery Revenue by Segment

DateOther countriesOther CountriesOUSOutside of USU.SUnited States
2022--32.9 M USD-43.96 M USD-
2021-28.99 M USD--34 M USD-
2020-19.78 M USD--22.27 M USD-
2019---28.79 M USD21.92 M USD-
2018---32.65 M USD28.21 M USD-
201731.86 M USD---32.45 M USD-
201627.11 M USD----37.76 M USD

Apollo Endosurgery SWOT Analysis

Strengths

Established Reputation: Apollo Endosurgery Inc has developed a strong reputation in the medical device industry due to its innovative and effective endosurgery products.

Technological Expertise: The company possesses a high level of technological expertise, enabling it to develop cutting-edge endoscopic devices and surgical instruments.

Strong Distribution Network: Apollo Endosurgery Inc has established a robust distribution network, allowing its products to reach a wide customer base globally.

Weaknesses

Limited Product Portfolio: The company's product portfolio is relatively limited compared to some of its competitors, which may restrict its market share and growth opportunities.

Financial Dependence: Apollo Endosurgery Inc relies heavily on external financing and investments, making it vulnerable to economic downturns and changes in investor sentiment.

Regulatory Challenges: The medical device industry is subject to complex and evolving regulations, exposing the company to potential compliance issues and delays in product approvals.

Opportunities

Increasing Surgical Procedures: As the demand for minimally invasive surgeries grows, Apollo Endosurgery Inc can capitalize on this trend by expanding its product offerings and targeting new surgical applications.

Emerging Markets: The company can explore untapped markets in developing economies, where access to advanced medical devices is increasing and healthcare infrastructure is improving.

Strategic Partnerships: Collaborating with healthcare providers, research institutions, and industry leaders can lead to valuable synergies, accelerate innovation, and enhance market reach for Apollo Endosurgery Inc.

Threats

Intense Competition: The medical device industry is highly competitive, with numerous companies vying for market share, which may create pricing pressure and erode profitability for Apollo Endosurgery Inc.

Intellectual Property Infringement: Protecting intellectual property rights is crucial in the medical device sector, as unauthorized use or imitation of Apollo Endosurgery Inc's technologies or products by competitors can harm the company's market position.

Economic Uncertainty: Economic downturns and volatile market conditions can impact healthcare spending, potentially reducing demand for Apollo Endosurgery Inc's products and services.

Apollo Endosurgery Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Apollo Endosurgery historical P/E ratio, EBIT multiple, and P/S ratio

Apollo Endosurgery shares outstanding

The number of shares was Apollo Endosurgery in 2023 — This indicates how many shares 40.65 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Apollo Endosurgery earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Apollo Endosurgery's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Apollo Endosurgery’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Apollo Endosurgery's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Apollo Endosurgery stock splits

In Apollo Endosurgery's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Apollo Endosurgery.

Apollo Endosurgery latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2022-0.21 -0.23  (-7.89 %)2022 Q4
9/30/2022-0.24 -0.28  (-18.34 %)2022 Q3
6/30/2022-0.23 -0.26  (-13.29 %)2022 Q2
3/31/2022-0.2 -0.21  (-4.69 %)2022 Q1
12/31/2021-0.2 -0.27  (-38.11 %)2021 Q4
9/30/2021-0.29 -0.23  (19.47 %)2021 Q3
6/30/2021-0.2 -0.22  (-9.67 %)2021 Q2
3/31/2021-0.22 -0.17  (24.24 %)2021 Q1
12/31/2020-0.26 -0.14  (46.17 %)2020 Q4
9/30/2020-0.21 -0.11  (48.65 %)2020 Q3
1
2
3
4
...
5

Apollo Endosurgery shareholders

%
Name
Stocks
Change
Date
13.00464 % CPMG, Inc.6,183,6032,219,96212/31/2022
9.98999 % Nantahala Capital Management, LLC4,750,161693,5341/4/2023
7.83732 % Stonepine Capital Management, LLC3,726,58401/4/2023
5.01913 % Citi Investment Research (US)2,386,557376,11912/31/2022
3.68040 % Deerfield Management Company, L.P.1,750,000012/31/2022
3.46051 % Archon Capital Management LLC1,645,443-196,64112/31/2022
3.11922 % Lytton (Laurence W)1,483,1621,183,9791/4/2023
3.08600 % The Vanguard Group, Inc.1,467,367105,58912/31/2022
2.25945 % J.P. Morgan Securities LLC1,074,3501,074,35012/31/2022
1.65473 % AWM Investment Company, Inc.786,809-43,28812/31/2022
1
2
3
4
5
...
10

Apollo Endosurgery Executives and Management Board

Mr. Charles McKhann53
Apollo Endosurgery President, Chief Executive Officer, Director (since 2021)
Compensation 8.59 M
Mr. Jeffrey Black53
Apollo Endosurgery Chief Financial Officer, Secretary
Compensation 2.95 M
Dr. Christopher Gostout71
Apollo Endosurgery Chief Medical Officer
Compensation 1.16 M
Mr. John Molesphini64
Apollo Endosurgery Executive Vice President - Operations
Compensation 654,476
Mr. John Barr64
Apollo Endosurgery Independent Chairman of the Board
Compensation 131,444
1
2
3

Apollo Endosurgery Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Olympus Stock
Olympus
SupplierCustomer0,740,69-0,180,570,210,72
1

Most common questions regarding Apollo Endosurgery

What values and corporate philosophy does Apollo Endosurgery represent?

Apollo Endosurgery Inc represents a strong commitment to bringing innovative and minimally invasive medical devices and solutions to the healthcare industry. With a focus on improving patient outcomes and enhancing quality of life, the company excels in providing effective solutions for weight loss and gastrointestinal disorders. Apollo Endosurgery Inc is known for its dedication to advancing medical technology and facilitating collaboration with healthcare professionals to address the evolving needs of patients. By combining clinical expertise and cutting-edge research, the company aims to revolutionize the field of endoscopic surgery and deliver superior value to patients, healthcare providers, and stakeholders.

In which countries and regions is Apollo Endosurgery primarily present?

Apollo Endosurgery Inc is primarily present in the United States.

What significant milestones has the company Apollo Endosurgery achieved?

Apollo Endosurgery Inc, a renowned medical technology company, has achieved several significant milestones over the years. One noteworthy accomplishment is the FDA approval of their flagship product, the Orbera Intragastric Balloon System. This innovative weight loss solution has helped numerous individuals achieve their weight loss goals. Additionally, Apollo Endosurgery's OverStitch Endoscopic Suturing System received FDA clearance, enabling minimally invasive endoscopic suturing procedures. These milestones demonstrate the company's dedication to enhancing patient care and advancing the field of endoscopy. Apollo Endosurgery Inc continues to develop groundbreaking medical technologies, solidifying its position as a leader in the industry.

What is the history and background of the company Apollo Endosurgery?

Apollo Endosurgery Inc is a renowned medical technology company focused on the development and commercialization of innovative gastrointestinal therapeutic solutions. Founded in 2006, the company has successfully established itself as a leader in the field of minimally invasive surgical and endoscopic technologies. Apollo Endosurgery is committed to providing effective and safe solutions for obesity, gastrointestinal disorders, and other related conditions. With a dedicated team of experts and a strong emphasis on research and development, the company continues to introduce cutting-edge products that positively impact patient outcomes. Apollo Endosurgery Inc has emerged as a trusted name in the medical industry, driving advancements in endoscopic procedures and revolutionizing patient care.

Who are the main competitors of Apollo Endosurgery in the market?

The main competitors of Apollo Endosurgery Inc in the market include companies such as Medtronic PLC, Johnson & Johnson, Boston Scientific Corporation, and Olympus Corporation.

In which industries is Apollo Endosurgery primarily active?

Apollo Endosurgery Inc is primarily active in the medical device industry.

What is the business model of Apollo Endosurgery?

Apollo Endosurgery Inc. operates in the medical device industry, specializing in the development and commercialization of therapeutic medical devices. The company focuses on minimally invasive surgical solutions for the treatment of obesity, gastrointestinal disorders, and other medical conditions. Apollo Endosurgery Inc. offers a portfolio of cost-effective and innovative product offerings, including the OverStitch™ Endoscopic Suturing System and the ORBERA® Intragastric Balloon System. By providing advanced medical technologies, Apollo Endosurgery Inc. aims to improve patient outcomes, enhance physician productivity, and ultimately revolutionize the field of endoscopy.

What is the P/E ratio of Apollo Endosurgery 2024?

The Apollo Endosurgery P/E ratio is -11.64.

What is the P/S ratio of Apollo Endosurgery 2024?

The Apollo Endosurgery P/S ratio is 3.66.

What is the Quality Investing of Apollo Endosurgery?

The Quality Investing for Apollo Endosurgery is 6/10.

What is the revenue of Apollo Endosurgery 2024?

The expected Apollo Endosurgery revenue is 111.2 M USD.

How high is the profit of Apollo Endosurgery 2024?

The expected Apollo Endosurgery profit is -34.92 M USD.

What is the business model of Apollo Endosurgery

Apollo Endosurgery Inc is a leading company that develops and manufactures medical devices and solutions for endoscopic surgery to treat obesity, GERD, and other gastrointestinal diseases.

What is the Apollo Endosurgery dividend?

Apollo Endosurgery pays a dividend of 0 USD distributed over payouts per year.

How often does Apollo Endosurgery pay dividends?

The dividend cannot currently be calculated for Apollo Endosurgery or the company does not pay out a dividend.

What is the Apollo Endosurgery ISIN?

The ISIN of Apollo Endosurgery is US03767D1081.

What is the Apollo Endosurgery WKN?

The WKN of Apollo Endosurgery is A2DJ26.

What is the Apollo Endosurgery ticker?

The ticker of Apollo Endosurgery is APEN.

How much dividend does Apollo Endosurgery pay?

Over the past 12 months, Apollo Endosurgery paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Apollo Endosurgery is expected to pay a dividend of 0 USD.

What is the dividend yield of Apollo Endosurgery?

The current dividend yield of Apollo Endosurgery is .

When does Apollo Endosurgery pay dividends?

Apollo Endosurgery pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Apollo Endosurgery?

Apollo Endosurgery paid dividends every year for the past 0 years.

What is the dividend of Apollo Endosurgery?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Apollo Endosurgery located?

Apollo Endosurgery is assigned to the 'Health' sector.

Wann musste ich die Aktien von Apollo Endosurgery kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Apollo Endosurgery from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Apollo Endosurgery pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Apollo Endosurgery in the year 2023?

In the year 2023, Apollo Endosurgery distributed 0 USD as dividends.

In which currency does Apollo Endosurgery pay out the dividend?

The dividends of Apollo Endosurgery are distributed in USD.

All fundamentals about Apollo Endosurgery

Our stock analysis for Apollo Endosurgery Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Apollo Endosurgery Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.